REDX is a clinical-stage R&D company focused on drugs targeting oncology and fibrotic disease. 2018 was a year that reset the benchmarks – new management team, restructured organisation focused on two therapeutic areas, and a clean balance sheet. 2019 will be characterised by a number of major milestones, including the recent restart of the Phase I/IIa trial with RXC004 with a revised protocol, and we note that RXC006 has been nominated as the first development candidate in the anti-fibrotic programme. Meanwhile, operating costs have been reduced while management considers all options available to strengthen its balance sheet.
11 Jul 2019
Phase I trial resumed
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Phase I trial resumed
Redx Pharma Plc (REDX:LON) | 12.8 0 0.0% | Mkt Cap: 49.6m
- Published:
11 Jul 2019 -
Author:
Martin Hall -
Pages:
16
REDX is a clinical-stage R&D company focused on drugs targeting oncology and fibrotic disease. 2018 was a year that reset the benchmarks – new management team, restructured organisation focused on two therapeutic areas, and a clean balance sheet. 2019 will be characterised by a number of major milestones, including the recent restart of the Phase I/IIa trial with RXC004 with a revised protocol, and we note that RXC006 has been nominated as the first development candidate in the anti-fibrotic programme. Meanwhile, operating costs have been reduced while management considers all options available to strengthen its balance sheet.